March 27, 2013 |
In findings that may represent a breakthrough in the treatment of hepatitis C infection, researchers have reported that weekly injections of an experimental medication that denies the virus a foothold in the liver substantially drove down subjects' viral loads after five weeks of treatment. Fourteen weeks after the injections ended, researchers found that five of 18 infected subjects getting the medication's higher doses showed no detectable trace of infection. The new study describes a treatment approach that could outsmart the hepatitis C virus's penchant for developing resistance to existing drugs and "provide curative therapy to a large proportion" of the 170 million people in the world who are infected with the virus, wrote Harvard University physician Dr. Judy Lieberman and Dr. Peter Sarnow of Stanford University.
November 29, 2012 |
WASHINGTON - A nomadic medical technician who wandered in and out of hospital jobs from the desert Southwest to New England was indicted Thursday by a federal grand jury in connection with a Hepatitis C outbreak that infected more than 30 patients at a New Hampshire hospital with the potentially life-threatening disease, and possibly 4,000 more in Pennsylvania, Maryland and other states. David M. Kwiatkowski, a 33-year-old former radiology tech, was charged with seven counts of tampering with a consumer product and seven counts of obtaining controlled substances by fraud.
November 29, 2012 |
WASHINGTON - A nomadic medical technician who held hospital jobs from Arizona to New England has been indicted in connection with a hepatitis C outbreak that infected more than 30 patients at a New Hampshire hospital and exposed thousands of others in Pennsylvania, Maryland and other states. David M. Kwiatkowski, a 33-year-old former radiology technician, was charged Wednesday by a federal grand jury with seven counts of tampering with a consumer product and seven counts of obtaining controlled substances by fraud, the Justice Department said Thursday.
August 21, 2012 |
I consider myself to be a fortunate person. I have a good education, a great job and excellent health insurance. I am a baby boomer who has aged reasonably well and can look forward to a fairly comfortable retirement. I am also fortunate because I was diagnosed with hepatitis C by a proactive and knowledgeable doctor in the late 1990s and had the opportunity to be treated and cured. The odds are that if I had not been diagnosed and treated, I would be on a liver transplant list right now, have liver cancer or even be dead from this disease.
July 20, 2012 |
Silymarin, an extract of milk thistle widely used around the world for treating liver disease caused by the hepatitis C virus, provides no more benefit than a placebo, researchers reported this week. Some estimates are that as many as a third of the estimated 3.2 million Americans with hepatitis C -- as well as many more millions around the world -- are consuming the drug in an effort to alleviate their symptoms. The new research by a team headed by Dr. Michael W. Fried of the University of North Carolina School of Medicine suggests that they are simply wasting their money.
June 12, 2012 |
More than a quarter of L.A.'s homeless adults are infected with the hepatitis C virus, and nearly half of them don't know it, UCLA researchers reported this week. Almost none of them have been treated for the infection, suggesting that the public health system could face a major financial burden as their infections progress to cirrhosis of the liver and end-stage liver disease. The hepatitis C virus, known as HCV, represents a potentially lethal infection. It is transmitted through the blood, primarily by needles used for injecting drugs.